title: Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent.
abstract: OBJECTIVE
  To compare strut coverage patterns between everolimus-eluting stent (EES) and first-generation drug-eluting stents (DES) at more than 12 months after successful implantation, using optical coherence tomography (OCT).
  
  
  BACKGROUND
  No sufficient OCT data has been reported comparing late strut coverage patterns between EES and first-generation DES. The favorable late results after EES implantation could be related to lower rates of uncovered and malapposed struts.
  
  
  METHODS
  A total of 66 DES (21 EES, 23 SES, and 22 PES) that were implanted at least 1 year in advance in 40 patients and met good late angiographic results were evaluated by OCT. The percentage of uncovered and malapposed struts, calculated as the ratio of uncovered or malapposed struts to total struts in all cross-sectional images per stent, was compared among the three groups.
  
  
  RESULTS
  A total of 35,061 struts were analyzed: 11,967 from EES, 11,855 from SES, and 11m239 from PES. The average tissue coverage thickness of the struts per stent was greater in EES than in SES and PES (109 ± 40 µm vs. 72 ± 27 µm and 83 ± 26 µm, respectively; P = 0.001). The percentage of uncovered struts (1.9 ± 4.1% in EES vs. 11.6 ± 12.7% in SES, P = 0.01 and vs. 7.1 ± 5.2% in PES, P < 0.001) and malapposed struts (0.1 ± 0.3% in EES vs. 1.8 ± 3.5% in SES, P = 0.01 and vs. 3.5 ± 5.1% in PES, P = 0.02) was much lower in EES than in first-generation DES, with no significant differences between SES and PES.
  
  
  CONCLUSIONS
  Late strut coverage patterns are not similar between EES and first-generation DES. EES showed a lower percentage of uncovered and malapposed struts.
authors.affiliation: Reina Sofia Hospital, Department of Cardiology, Avenida Menéndez Pidal 1, 14004, Córdoba, Spain.
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Toledano Delgado
authors.forename: Manuel Pan
authors.initials: MP
authors.lastname: Alvarez-Ossorio
authors.forename: José Suárez
authors.initials: JS
authors.lastname: de Lezo Cruz-Conde
authors.forename: Francisco Mazuelos
authors.initials: FM
authors.lastname: Bellido
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Romero Moreno
authors.forename: Alfonso Medina
authors.initials: AM
authors.lastname: Fernández-Aceytuno
authors.forename: Javier Suárez
authors.initials: JS
authors.lastname: de Lezo Herrerosde Tejada
authors.forename: Soledad Ojeda
authors.initials: SO
authors.lastname: Pineda
authors.forename: José María Segura
authors.initials: JM
authors.lastname: Saint-Gerons
authors.forename: Djordje
authors.initials: D
authors.lastname: Pavlovic
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D015331:Cohort Studies; D017023:Coronary Angiography / Q000379:methods; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D003430:Cross-Sectional Studies; D054855:Drug-Eluting Stents; D019544:Equipment Failure Analysis; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012680:Sensitivity and Specificity; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D041623:Tomography, Optical Coherence / Q000379:methods*
chemical_list: D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus
keywords: drug delivery; malapposed struts; neointimal coverage; optical coherence tomography; stent structure; uncovered struts